Technology | February 03, 2014

FDA Approves Medtronic’s Valiant Captivia Thoracic Stent Graft System for Aortic Dissections

Medtronic Valiant Captivia Thoracic Stent Graft System Aneurism Repair AAA TAA
February 3, 2014 — The U.S. Food and Drug Administration (FDA) Medtronic Inc.’s Valiant Captivia Thoracic Stent Graft System to treat type B aortic dissections.
 
Supported by the results of the U.S. Medtronic DISSECTION trial, the new indication provides physicians a minimally invasive alternative to open surgical repair and medical therapy.
  
12-month data from the 50 patients evaluated in DISSECTION demonstrate safety and efficacy of the Valiant Captivia System in the treatment of dissections, with technical success.
 
Conducted at 16 U.S. sites, the trial met its primary safety endpoint by achieving an 8 percent all-cause mortality rate at 30 days, which represents a three- to four-fold mortality improvement over open surgical repair. 100 percent technical success and 100 percent coverage of the primary entry tear at implant were achieved in the trial.
 
Indicated for a variety of thoracic aortic lesions, the Valiant Captivia System features a proximal tip-capture mechanism, enabling controlled deployment and accurate placement of the stent graft. The Valiant stent graft maintains apposition to the vessel wall regardless of angulation or oversizing. Since its initial 2005 launch in Europe, the Valiant stent graft has been implanted in about 50,000 patients worldwide.
 
Medtronic expanded the size matrix of the Valiant Captivia Thoracic Stent Graft System with 11 proximal FreeFlo tapered pieces. This increased configuration possibilities by 30 percent to address a wider range of patient anatomies. The line extension enables physicians to use the thoracic stent graft system in tapered aortas, which account for approximately 20 percent of all thoracic aortic aneurysm cases. The pieces all taper by 4 mm along their approximately 150 mm length, and have proximal diameters ranging 26 mm to 46 mm. These additional system components received FDA approval, CE marking and Health Canada approval in January 2013. In Europe, they are approved for use in treating thoracic aortic aneurysms, transections and dissections; in the United States, for thoracic aortic aneurysms and transections; and in Canada, for thoracic aortic aneurysms.
 
For more information: www.medtronic.com

Related Content

FDA Grants Breakthrough Device Designation for Valiant Thoracoabdominal Aortic Aneurysm Stent Graft
News | Stent Grafts | October 09, 2019
Medtronic plc announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA...
PQ Bypass Granted IDE Approval to Start TORUS SFA Stent Graft Pivotal Study
News | Stent Grafts | October 08, 2019
PQ Bypass Inc. announced it has received full approval of its investigational device exemption (IDE) trial of the...
First U.S. Patient Receives Gore Tag Conformable Thoracic Stent Graft With Active Control
News | Stent Grafts | July 10, 2019
W. L. Gore & Associates Inc. (Gore) announced the first U.S. implant of the Gore Tag Conformable Thoracic Stent...
Gore Receives FDA Approval for Gore Tag Conformable Thoracic Stent Graft
Technology | Stent Grafts | May 15, 2019
W. L. Gore & Associates Inc. (Gore) announced the U.S. Food and Drug Administration (FDA) has granted regulatory...
Aortic Stent Graft Global Market to Reach $5.4 Billion by 2028
News | Stent Grafts | February 14, 2019
Abdominal aortic stent grafts will remain the largest segment in the global aortic stent graft market at least through...
Medtronic Receives FDA Approval for Valiant Navion Thoracic Stent Graft System
Technology | Stent Grafts | February 07, 2019
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for the Valiant Navion thoracic stent...
Endologix Ends Unrestricted Sales and Use of Nellix System
News | Stent Grafts | January 07, 2019
January 7, 2019 — Endologix Inc.
Endologix Reports Positive One-Year Results From the Ovation LUCY Study
News | Stent Grafts | July 16, 2018
Endologix Inc. announced one-year results from the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for...
FDA Committee Votes in Favor of Incraft AAA Stent Graft System
News | Stent Grafts | June 13, 2018
Cardinal Health announced that its Incraft Abdominal Aortic Aneurysm (AAA) Stent Graft System has received a favorable...
First Patient Enrolled in Gore Excluder Investigational Study
News | Stent Grafts | January 08, 2018
January 8, 2018 — W. L. Gore & Associates Inc.
Overlay Init